The Skinny on Diabetes Drugs

Sometimes, side effects can be a good thing. Really.

The goal of diabetes drugs is to get the patient's blood glucose levels under control, but one class of drugs, called GLP1 agonists, have a nice side effect: weight loss. About 90% of type 2 diabetics are overweight or obese, so most of the potential patients can thrive with a beneficial side effect.

So far, Amylin Pharmaceuticals (Nasdaq: AMLN  ) and Eli Lilly's (NYSE: LLY  ) Byetta is the only GLP1 agonist on the market, but that's likely to change.

Fewer injections. More sales?
Byetta garnered just $679 million in sales last year, well short of a blockbuster even though it has been on the market since 2005. The main reason for the lackluster performance is that it has to be injected twice a day. That's a lot of injections when oral diabetes drugs work well at controlling glucose levels -- even if they don't have that nice weight-loss side effect.

Novo Nordisk (NYSE: NVO  ) is hoping it'll be able to top that with its once-daily injection, liraglutide. The Food and Drug Administration already has the marketing application for the drug on its desk, but the agency isn't likely to make its PDUFA goal of March 23; the FDA has scheduled an advisory panel meeting for the beginning of April to get experts' input on whether the drug should be approved. The FDA has become a lot more cautious with diabetes drugs after potential heart problems with GlaxoSmithKline's (NYSE: GSK  ) Avandia were discovered.

Not to be outdone, Amylin and Eli Lilly are developing a once-weekly version of Byetta using Alkermes' long-lasting technology. The companies are planning to file a marketing application with the FDA before the end of the second quarter after they prove that the drug used in the successful phase 3 trial is equivalent to the stuff being produced in their new manufacturing plant. That shouldn't be a major obstacle, but with drug development, nothing is certain.

At the moment, it looks to me like Amylin and Eli Lilly are in the driver's seat. Some patients may switch to liraglutide when it's approved, but with once-weekly Byetta hot on its heels, doctors may recommend that patients wait and switch from the short-acting to the long-acting version of Byetta rather than switch back and forth between molecules.

In the pipeline
But wait, there's more! This is far from a two-person race. Roche has a GLP1 drug, taspoglutide, in phase 3 trials, and this week Glaxo announced that it's going to start a phase 3 trial for Syncria, a drug in the same class that was developed using technology from Human Genome Sciences (Nasdaq: HGSI  ) . Both offer dosages of once a week.

Being behind liraglutide and Byetta could be problematic, but these two latecomers could easily take market share from whichever drug is the established leader at the time if they can show that they work better, or perhaps if they have more of that wonderful weight-loss side effect, or a better safety profile -- Byetta has been linked to reports of pancreatitis.

If not, there's the risk that these me-too drugs could fall flat on their faces. Neither Johnson & Johnson's (NYSE: JNJ  ) antipsychotic Invega nor Wyeth's (NYSE: WYE  ) antidepressant Pristiq have wowed patients or investors with their launches. Roche and Glaxo are taking a risk being late to the party, although it's still possible that it'll pay off.

Going with a pill
Actually, all the drugmakers are taking a big risk in developing GLP1 drugs because they have to be injected. Patients don't want to inject themselves if they don't have to. For instance, Merck's oral medication Januvia was approved a year after Byetta, but managed $1.4 billion in sales last year. Once-weekly injections will certainly trump once- or twice-daily injections, but only time will tell whether the pokes are infrequent enough to divert patients from the oral medication.

Novo Nordisk seems to have realized this and is developing an oral GLP1 drug using technology from an Irish company called Merrion Pharmaceuticals. Any drug from that partnership is many years away from the market, but it could be a blockbuster if it has the same effect as the injected drugs -- weight loss included.

Diabetes isn't going away anytime soon, and investors would be smart to keep an eye on the GLP1 drug fight. It could increase your portfolio's value.

More Foolishness:

Novo Nordisk is a Motley Fool Global Gains selection. Johnson & Johnson and GlaxoSmithKline are Income Investor recommendations. Try any of our Foolish newsletters today, free for 30 days

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. The Fool has a disclosure policy.


Read/Post Comments (5) | Recommend This Article (6)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On February 20, 2009, at 9:36 PM, magnoliacottage wrote:

    Actually weight loss is considered a clinical effect of BYETTA, not a side effect. If you study the package insert you will see that weight effect is listed under the "Clinical Studies" section of the PI, not the "Adverse Reactions" section. See the following website: http://pi.lilly.com/us/byetta-pi.pdf

  • Report this Comment On February 21, 2009, at 1:25 AM, DannyHaszard wrote:

    Eli Lilly's # 1 cash cow Zyprexa has been overprescribed and linked to a ten times greater risk of causing type #2 diabetes.

    Byetta is treatment for the diabetes caused by the first drug.

    WOW! Daniel Haszard Zyprexa patient who got the diabetes from it. www.zyprexa-victims.com

  • Report this Comment On February 21, 2009, at 7:43 AM, randeg wrote:

    It's good to have all this information to guide one in the choice of the best fit. At least the diabetics will have a choice among oral medications and the ones that can be injected. Even among the latter one, there is the choice depending upon the number of injections one can tolerate.

    Evelyn Guzman

    http://www.free-symptoms-of-diabetes-alert.com (If you want to visit, just click but if it doesn’t work, copy and paste it onto your browser.)

  • Report this Comment On February 21, 2009, at 8:07 PM, Infratious wrote:

    What about MannKind's inhaled drug? There's no mention here. The company is about to submit it's marketing application to the FDA. It's safe, effective, and way more conveniently packaged than Exubera's disaster.

  • Report this Comment On February 24, 2009, at 2:33 AM, FYDL531 wrote:

    This really was a great help- managing your way through all the different types of diabetes drugs can be so hard- but it's very interesting to hear what's going on in this part of pharmaceutical research. I've found some great articles like this on www.dlife.com, its got loads of information if you want to know more about diabetes drugs!

Add your comment.

DocumentId: 836132, ~/Articles/ArticleHandler.aspx, 4/24/2014 5:27:36 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement